抗SARS-CoV血清抗体体外抗SARS病毒实验研究  

Anti-SARS-CoV capability of remedial horse anti-SARS-CoV immunoglobulins

作　　者：纪晓光[1] 赵光宇[1] 石辛甫[1] 张良艳[1] 张松乐[1] 赵艳红[1] 王京燕[1] 王希良[1] 

机构地区：[1]中国人民解放军军事医学科学院微生物流行病研究所病原微生物生物安全国家重点实验室,北京100071

出　　处：《免疫学杂志》2006年第5期503-505,共3页Immunological Journal

基　　金：十五"863"计划重大项目(2003AA208212;2003AA208218);全军非碘性肺炎防治重大科技项目(03F003-3)资助

摘　　要：目的研究三个批号的抗SARS-Cov血清抗体体外对SARS-CoV的抑制作用。方法采用MTT法,观察药物对SARS-Cov的抑制作用。结果MTT法测得三个批号的抗SARS-CoV血清抗体的最大无毒浓度均小于10μg/mL。不同时间点的治疗指数(TI)2h组>6h组>12h组>24h组;不同批号的治疗指数(TI)200307批>200306批>200308批。结论在本实验条件下抗SARS-CoV血清抗体体外有一定的抗SARS-CoV作用,为其治疗SARS-CoV感染提供了实验依据。Objective To observe the anti-SARS-CoV effects of remedial horse anti-SARS-CoV serum antibody in vitro. Methods The antiviral activity of remedial horse anti-SARS-CoV serum antibody was studied by MTT colorimetry. Results The maximal tolerance dosage （TD0） of the three batches （No.200306, No.200307, and No.200308） of remedial anti-SARS-CoV serum antibody on Vero-E6 were all 〈 10μg/mL. Treatment indexes （TI） of four time-points of remedial anti-SARS-CoV serum antibody were in the order of TI2 h 〉 TI6 h 〉 TI12 h 〉 TI24 h; TI of these three batches of remedial anti-SARS-CoV serum antibodies were in the order of TI200307 〉 TI200306 〉 TI200308. Conclusion Remedial horse anti-SARS-CoV serum antibody has anti-SARS-CoV activity in vitro. This study provides the experimental evidences for the clinical use of antiviral treatment in the SARS-CoV infection.

关 键 词：抗SARS-CoV血清抗体体 SARS-COV MTT法 

分 类 号：R392[医药卫生—免疫学]